<DOC>
	<DOCNO>NCT01130597</DOCNO>
	<brief_summary>The purpose study evaluate feasibility individualize titration patiromer accord serum potassium . This study also assess safety tolerability patiromer effect patiromer serum potassium heart failure ( HF ) participants chronic kidney disease ( CKD ) .</brief_summary>
	<brief_title>Evaluation Patiromer Titration Heart Failure Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This open-label , single-arm study evaluate titration regimen patiromer approximately 63 HF participant CKD receive one following : angiotensin-converting enzyme inhibitor ( ACEIs ) , angiotensin II receptor blocker ( ARBs ) , beta blocker ( BBs ) . This study consider exploratory . Upon successful completion screen evaluation ( -10 -5 day prior enrollment ) , eligible participant assign Baseline ( Day 0 visit ) initial dose patiromer ( 20 g/day ) spironolactone ( 25 mg/day ) . Study visit enrol participant schedule Days 3 , 7 , 14 , 21 , 28 , 35 , 42 , 49 56 . A follow-up visit occur Day 63 . At select study visit , patiromer spironolactone dos may titrate . The study dose algorithm design maintain individual 's serum potassium value range 4.0 - 5.1 mEq/L ( base local lab data ) . Any participant local laboratory serum potassium value &lt; 3.5 &gt; 5.5 mEq/L two consecutive schedule study visit , despite titration patiromer spironolactone , withdrawn study , permanently discontinue patiromer spironolactone , return follow-up visit within 7 day .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Chronic HF clinically indicate receive spironolactone therapy 2 . Age 18 year old 3 . Local laboratory serum potassium value 4.3 5.1 mEq/L screen baseline 4 . CKD ( estimate glomerular filtration rate [ eGFR ] &lt; 60 mL/min/1.73m2 screen base central lab creatinine measurement ) 5 . On least one follow HF therapy : ACEI , ARB , BB 6 . Females childbearing potential must nonlactating , must negative serum pregnancy test screening , must use highly effective form contraception least 3 month study drug administration , study , one month study completion 7 . Male participant and/or female partner childbearing potential must use highly effective form contraception study 3 month study completion 8 . Provide write informed consent prior participation study 1 . History bowel obstruction , swallow disorder , severe gastrointestinal disorder major gastrointestinal surgery 2 . Uncorrected primary severe valvular disease , know obstructive restrictive cardiomyopathy , uncontrolled hemodynamically unstable arrhythmia 3 . Coronaryartery bypass graft , percutaneous intervention ( e.g. , cardiac , cerebrovascular , aortic ) , major surgery include thoracic cardiac , within 3 month prior baseline anticipate need study participation 4 . Heart transplant recipient , anticipate need transplant study participation 5 . Any following event occur within 2 month prior baseline : unstable angina judge Investigator , unresolved acute coronary syndrome , transient ischemic attack stroke 6 . Current dialysis participant , anticipate need dialysis study participation 7 . Prior kidney transplant , anticipate need transplant study participation 8 . Metastatic , latestage endstage cancer &lt; 12 month life expectancy risk tumor lysis syndrome 9 . History alcoholism drug/chemical abuse within 1 year 10 . Sustained systolic blood pressure &gt; 180 &lt; 90 mmHg 11 . Liver enzymes [ alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ] &gt; 3 time upper limit normal 12 . Loop thiazide diuretic stable least 21 day prior baseline anticipate remain stable study participation 13 . Use intravenous cardiac medication within 21 day prior baseline , anticipate need study participation 14 . Current use polymerbased drug ( e.g. , sevelamer , sodium polystyrene sulfonate , colesevelam , colestipol ) , phosphate binder ( e.g. , lanthanum carbonate ) , potassium binder , anticipate need study participation 15 . Use potassium spar medication include aldosterone antagonist potassium supplement last 21 day prior baseline 16 . Use investigational medication within 30 day 5 halflives , whichever longer , prior baseline 17 . Participants take investigational product study , previous patiromer study 18 . Inability consume study medication , , opinion Investigator , inability comply protocol 19 . In opinion Investigator , medical condition , uncontrolled systemic disease , serious intercurrent illness , extenuate circumstance occur persisting , within 30 day prior baseline , would significantly decrease study compliance jeopardize safety participant affect validity trial result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HF</keyword>
	<keyword>Heart failure</keyword>
	<keyword>hyperkalemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>prevention hyperkalemia heart failure participant</keyword>
</DOC>